← Leaderboards
Anthony Cammarato
Johns Hopkins University
$4,199,816
Attributed
$4,199,816
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $595K · FY2014–25$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,199,816 · 2
By mechanism
R01$3,817,136 · 1
R56$382,680 · 1
Top collaborators
No co-investigators on record.
Most similar at Johns Hopkins University
Same institution · by research overlap
- David Alan Kass$45,555,857
- Anne M Murphy$9,234,720
- Chirag R Parikh$38,095,595
- Douglas N Robinson$9,316,873
- Chiadi E Ndumele$8,378,055
Others in their field
Top investigators on “In Vitro”
- David Heimbrook · Leidos Biomedical Research, Inc.$553,787,942
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Dennis R. Burton · Scripps Research Institute$79,204,175
Research focus
In VitroIn VivoF-ActinEnvironmental Risk FactorInsightGeneticComplexDefectDrosophila GenusElementsHypertrophic CardiomyopathyGenotypeAmino AcidsBinding SitesBiological ModelsAnimal ModelCardiacAffectCardiomyopathiesActinsDrosophila MelanogasterChargeCommunicationLead
Grant awards (9)
PATHOGENESIS AND IN VIVO SUPPRESSION OF THIN FILAMENT-BASED CARDIOMYOPATHIES$500,424
R01 · FY2025 · HL · contact PI
PATHOGENESIS AND IN VIVO SUPPRESSION OF THIN FILAMENT-BASED CARDIOMYOPATHIES$567,443
R01 · FY2024 · HL · contact PI
PATHOGENESIS AND IN VIVO SUPPRESSION OF THIN FILAMENT-BASED CARDIOMYOPATHIES$579,024
R01 · FY2023 · HL · contact PI
PATHOGENESIS AND IN VIVO SUPPRESSION OF THIN FILAMENT-BASED CARDIOMYOPATHIES$594,962
R01 · FY2022 · HL · contact PI
Pathogenesis and in vivo suppression of thin filament based cardiomyopathies$399,233
R01 · FY2018 · HL · contact PI
Pathogenesis and in vivo suppression of thin filament based cardiomyopathies$414,730
R01 · FY2017 · HL · contact PI
Pathogenesis and in vivo suppression of thin filament based cardiomyopathies$394,610
R01 · FY2016 · HL · contact PI
Pathogenesis and in vivo suppression of thin filament based cardiomyopathies$366,710
R01 · FY2015 · HL · contact PI
Pathogenesis and in vivo suppression of thin filament based cardiomyopathies$382,680
R56 · FY2014 · HL · contact PI